reports
NMRC Reports Results for Campylobacter Controlled Human Infection Mode...
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylob...
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Plans Phase 2 Trial for IMM-529 following FDA review Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce th...
Immuron Announces New U.S. Department of Defense Research Award for Na...
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Co...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Confer...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. Steven...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Con...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questi...
Immuron announces record Travelan® sales globally, Australia and USA
Immuron announces record Travelan® sales globally, Australia and USA Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7 million up 223% on pcp • June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA• FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada• FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, July 15, 20...
Immuron requests pre-IND meeting for IMM-529 with FDA filing
Immuron requests pre-IND meeting for IMM-529 with FDA filing MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. CEO, Steven Lydeamore said, “We are excited for our third therapeutic to be heading towards Phase 2 clinical studies, demonstrating the utility of our technology platform.” The increased incidence of an...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Confer...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. Steven L...
Immuron CEO Steven Lydeamore to present at Peak Sky High
Immuron CEO Steven Lydeamore to present at Peak Sky High MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024. A copy of the presentation slide deck is available on the Company’s website. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steve...
Immuron Board Changes
Immuron Board Changes MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strateg...
Immuron Limited to Present at the Emerging Growth Conference
Immuron Limited to Present at the Emerging Growth Conference MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give existing shareholders and the investme...
Immuron Director Resignation
Immuron Director Resignation MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen’s tenure, Immuron launched Travelan® into the USA and Canadian markets and dual listed the Company on NASDAQ (I...
Immuron to host Live Virtual Event
Immuron to host Live Virtual Event MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT. TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALSExploring Immuron’s Positive Phase 2 Travelan® Results and Upc...
Immuron Travelan® sales continued strong growth
Immuron Travelan® sales continued strong growth Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, Apr...
Immuron Announces Positive Results Support Travelan® progress to Phase...
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (se...
Immuron Presentation Australian Biologics Festival 2024
Immuron Presentation Australian Biologics Festival 2024 MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia. A copy of the presentation slide deck is available on the Company’s website. Authorised for release by the Board of Immuron Limited. COMPANY CONTACT:Steven LydeamoreCh...
Immuron achieves record Travelan® sales
Immuron achieves record Travelan® sales Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6 millionCanadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacte...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron CEO, Steven Lydeamore Investor Webinar Presentation MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia. A copy of the presentation slide deck is available on the Company’s website. Authorized for release by the Board of Immuron Limited. COMPANY CONTACT:Steven Lydeamore Chief Executiv...
Immuron achieves record half yearly Travelan® sales
Immuron achieves record half yearly Travelan® sales Highlights: Record half yearly Travelan® sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Austral...
Immuron Clinical Trials Update
Immuron Clinical Trials Update Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completedPre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is ple...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.